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CASE PRESENTATION
Among 243 patients who received kidney transplants at
our center, two patients suddenly developed a severe
debilitating pain syndrome in the lower limbs.
Case no. 1
A 49-year-old male patient who received a deceased donor
kidney transplant, in therapy with tacrolimus (plus steroids
and perioperative basiliximab). One month after transplant-
ation he reported joint pain in his ankles, knees, feet, and
hands. The pain became so intense that the patient was
forced to use crutches to walk. Clinical examination revealed
intense pain at movement, without edema, redness, increase
in temperature, or cutaneous trophic alterations. The patient
was receiving tacrolimus 5 mg b.i.d. with levels between 5 and
10 ng/ml. There was no clinical or serologic evidence of
rheumatic disease or rhabdomyolysis. The rise in serum
creatinine was attributed to heavy non-steroidal anti-
inflamatory drug use. After withdrawing these agents, the
serum creatinine decreased to 1.6 mg/dl. Bone radiographies
showed osteoporosis at the heads of the knee, ankle, tarsal,
and metatarsal bones. An ultrasound scan of the joints
highlighted a minimal amount of articular effusion and a
mild synovial reaction in the knee and foot joints. Magnetic
resonance imaging (MRI) of the left knee showed an area of
bone marrow edema in the external condyle of the femur and
wearing of the cartilage (Figure 1). Computerized bone
mineralometry showed a slight reduction of the bone mass,
whereas bone scintigraphy revealed increased radionuclide
uptake in the affected joints (Figure 2).
Case no. 2
A 42-year-old obese male patient received a deceased donor
kidney transplant and underwent therapy with cyclosporine,
Everolimus (1 mg b.i.d.) and steroids, plus perioperative
basiliximab. The patient was already undergoing therapy with
calcium antagonists for arterial hypertension. Six months
after transplantation, the patient began to complain of pain
in his feet that rendered walking difficult. The dose of
cyclosporine at this point was 100 mg b.i.d., with C0 levels of
168 ng/ml. On clinical examination, intense pain was caused
even by passive movement of the tibial-tarsal joints but there
were no signs of vasomotor instability. Laboratory tests did
not reveal any significant changes, radiography of the feet
showed patchy osteoporosis and computerized bone miner-
alometry revealed marked demineralization. An ultrasound
scan of the feet did not show any alterations. Three months
after the onset of the syndrome, the symptoms became so
serious that the patient was confined to bed.
CLINICAL FOLLOW-UP
Case no. 1
Tacrolimus was suspended owing to the suspicion of
Calcineurin-inhibitor induced pain syndrome (CIPS) and
mycophenolate mofetil and steroid therapy was commenced,
with a subsequent improvement in the clinical picture. Follo-
wing acute rejection 5 months later, the patient was treated
with steroid boluses and tacrolimus was re-introduced at
2 mg b.i.d. Symptoms gradually receded and 8 months after
the onset of the syndrome the patient was completely
symptom-free.
Case no. 2
Owing to concomitant hyperlipidemia, Everolimus was
suspended whereas cyclosporine and steroids were continued.
The symptoms gradually regressed until they disappeared
altogether after 2 months, 7 months from their onset without
any specific therapy.
DISCUSSION
Since the last decade, reports of a debilitating post-transplant
pain syndrome have been emerging.
The syndrome seems to affect about 5% of patients who
undergo kidney, heart, lung, liver, pancreas, or bone marrow
transplantation,1 is associated with the use of calcineurin
inhibitors (cyclosporine and tacrolimus) and has in the past
been attributed to various pathologies, in particular Reflex
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Sympathetic Dystrophy Syndrome (RSDS). However, only a
few authors have presented cases with symptoms and signs
consistent with a definite diagnosis of this disease. CIPS, as
described for the first time by Grotz et al.2 in 2001, seems to
be a distinct pathology with specific physical symptoms,
clinical, and laboratory signs, a characteristically favorable
prognosis and spontaneous resolution.
Muscular, joint, and bone pain in transplant patients are
not new phenomena, especially in renal transplantation,3–5
caused by various pathologies. Since the introduction of
calcineurin inhibitors we have witnessed the appearance of
this new complication, difficult to classify, characterized by
unknown physiopathological mechanisms and a lack of
clearly defined therapeutic protocols. Many authors have
linked this syndrome to RSDS, described for the first time by
Mitchell et al.6 over 100 years ago. According to these authors
the calcineurin inhibitors could be responsible for direct
neurotoxicity or for stimulating the sympathetic system or
interfering with neuromediators.7 In 1981 Kozin et al.8
proposed the currently accepted diagnostic criteria for RSDS:
(1) constant intense bone pain, generally of hands, feet, or
knees: the pain is often asymmetric, although it can also
be bilateral, and usually asynchronous;
(2) signs and symptoms of vasomotor instability: increased
temperature of the skin or sweating;
(3) edema of the extremities; and
(4) trophic skin changes.
An analysis of the literature on this syndrome, however,
shows many points in conflict with a certain diagnosis of
RSDS (Table 1). Firstly, at least two of Kozin’s criteria –
namely vasomotor instability and trophic skin alterations –
seem to be lacking in almost all cases. In 1991 Munoz-Gomez
et al.3 and Lucas et al.9 analyzed two series of patients who
received kidney transplants describing some cases of severe
pain in the knees and ankles, occurring between 1 and 3
months after transplantation. All patients were given
monotherapy with cyclosporine. Radiography showed signs
of patchy osteoporosis in some cases, whereas scintigraphy
highlighted an increased periarticular tracer uptake. Symp-
toms improved when the dose of cyclosporine was reduced
and disappeared a few months later.
In 1994 and 1995 Sanchez et al.,4 Gauthier and Barbosa10
Stevens et al.11 published some cases of severe lower limb
pain arising within the first 2 months after renal transplanta-
tion. The pain was mainly localized in the knees and
sometimes the ankles, was not associated with any particular
physical signs and the only common feature was an increased
tracer uptake in the affected bones and joints at scintigraphy.
The symptoms receded spontaneously in all cases.
In 1998 Grandtnerova et al.12 and Pilmore et al.,13
described more cases of pain arising 2–3 months after renal
transplant. In 1999 Torregrosa and Campistol7 published a
review on post-transplant RSDS in patients treated with cyclo-
sporine, with a prevalence between 1 and 10%. Symptoms
usually arose in the first 3 months post-transplant and lasted
3–6 months before spontaneous resolution. The authors
concluded that there was no specific therapy currently
available, but they recommended the introduction or increase
of steroid therapy. Furthermore, given that the symptoms
only appeared with the use of cyslosporine, they suggested
substituting cyclosporine with tacrolimus. In the same year,
however, Villaverde et al.14 published the first case of lower
limb bone pain in a renal transplant patient treated with
tacrolimus. The following year Puig I Mari et al.1 reported
Figure 1 | MRI of the left knee showing an area of bone marrow
edema in the external condyle of the femur.
R L 
Figure 2 | Bone scintigraphy: increased radionuclide uptake in
the affected joints.
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another case of lower limb pain in a renal transplant patient
undergoing tacrolimus therapy. Despite the fact that the
dosage of tacrolimus was not changed, the symptoms
disappeared completely 4 months later. The authors consider
this to be a case of RSDS and the symptoms did correspond
to the diagnostic criteria for RSDS: the pain was asymmetric
and there were signs of vasomotor instability.
In 2001 Grotz et al.2 described some cases of osteoarticular
lower limb pain in patients being treated with cyclosporine or
tacrolimus after renal transplantation. This is the first time
that CIPS was mentioned. Pain began between 3 and 14
months after transplantation, was localized symmetrically in
both feet and sometimes in the ankles and knees, and was so
debilitating that several patients were forced to walk with
crutches or use wheelchairs. Clinical examination proved
generally negative and blood tests were normal. Radio-
graphies showed no abnormalities, whereas bone scintigraphy
showed intense tracer uptake. MRI highlighted bone marrow
edema in the painful areas. Pain ceased between 3 and 18
months from the onset of symptoms following a reduction of
the immunosuppressors dose. The second mention of CIPS
appeared in Malat et al.15 case report of 2002, where the case
of a 13-year-old boy treated with tacrolimus after a liver
transplant is discussed.
In 2002 and 2003 Coates et al.16 and Goffin et al.17
presented more cases of lower limb bone pain occurring in
the first months after surgery in renal transplant patients
receiving cyclosporine or tacrolimus. In all of these cases the
pain was bilateral and severely debilitating and the symptoms
ceased spontaneously within a few months. Finally in 2003
Ybarra et al.18 presented four cases described as RSDS,
although they themselves admitted that the cases did not
entirely fulfil the classic diagnostic criteria.
Only the cases reported by Munoz-Gomez et al.3 seem to
fulfil the criteria for a diagnosis of RSDS, yet even in this
instance the authors admitted that they were dealing with a
cyclosporine-related syndrome with RSDS-like character-
istics. It is therefore probable that the syndrome is the same,
characterized by a sudden onset of severe bilateral pain in the
lower limbs correlated to immunosuppression with calci-
neurin inhibitors and spontaneous resolution. CIPS is a
different entity from RSDS, with which it has only some
aspects in common. Its pathogenesis has yet to be clarified: it
has been hypothesized that calcineurin-inhibitors provoke
vascular changes with disturbance of bone perfusion and
permeability that in turn causes intraosseous vasoconstric-
tion and bone marrow edema. These signs are detectable by
MRI (especially in the distal tibia) and by bone scintigraphy,
where an increased tracer uptake is a sign of hypervascular-
ization, hyperperfusion, and hypermetabolism. The bones of
the lower limbs are preferentially affected because they are
subjected to greater venous blood pressure when the
patient is standing. Typical clinical presentation consists
of symmetric pain in the lower limbs, involving the bones of
the feet, ankles, and knees, that begins one or a few months
after the initiation of immunosuppressive therapy and
resolves itself spontaneously within a few months. Pain
worsens when walking and standing and is slightly alleviated
by resting the legs in a raised position. The pain is
characteristically bilateral and symmetric and affects the
distal extremities of the lower limbs.1,19 It does not involve
the hips or spine like osteoporosis and does not include
the trophic skin changes or signs of vasomotor instability
typical of RSDS. Blood tests show no changes in inflamma-
tory or rheumatological parameters and the serum concen-
trations of cyclosporine or tacrolimus are often within
normal ranges. Clinical examination does not reveal
particular pathological signs.
The three typical radiological signs of CIPS are the
normality of the X rays, which at most show a certain degree
of osteoporosis, the increased tracer uptake in the affected
bones and joints at bone scintigraphy, and patchy edema of
the bone marrow and periarcticular soft tissue visible
by MRI.








Munoz Gomez 1991 7/240 Kidney CsA Yes
Lucas et al. 1991 26/234 Kidney CsA No
Naredo Sanchez 1994 1 Kidney CsA No
Gauthier and Barbosa 1994 15 Lung/Liver/Kidney/Pancreas CsA No
Stevens 1995 4/386 Kidney CsA No
Grantnerova 1998 3/147 Kidney CsA Yes
Pilmore 1998 2 Kidney CsA No
Villaverde et al. 1999 1 Kidney Tac No
Puig I Mari 2000 1 Kidney Tac Yes
Grotz 2001 9/637 kidney 1/39
heart
Kidney /Heart CsA/Tac No
Malat 2002 1 Liver Tac No
Coates 2002 4/134 Kidney CsA No
Goffin 2003 5/101 Kidney Tac No
Ybarra 2003 4 Kidney CsA/Tac No
Present series 2006 2/243 Kidney CsA/Tac No
CsA, cyclosporine; Tac, tacrolimus.
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CIPS is a rare but debilitating side effect of cyclosporin
and tacrolimus and should be recognized as a distinct post-
transplant pain syndrome, given its characteristic course and
favorable prognosis, and especially considering that therapies
proposed for other pain syndromes are at best useless and at
worst damaging for CIPS sufferers. The diffusion of
information about this syndrome is all the more necessary
considering that as recently as 2003 some authors suggested
switching therapy from cyclosporine to tacrolimus, when it
has been proven that the syndrome also appears during use of
the latter.
At the moment there is no certain information regarding
how best to treat CIPS. It is commonly accepted that non-
steroidal anti-inflammatory drugs therapy should be avoided
because of the possible deterioration of renal function. The
use of clodronate and calcitonin seems to help attenuate pain
by inhibiting osteolysis (calcitonin also seems to have a
central effect).20 The reduction of calcineurin inhibitor doses,
even in the presence of normal blood values, seems to
alleviate pain symptoms.2 Resting the legs in a raised position
is recommended. The use of calcium antagonists (preferably
nifedipine or nitrendipine), which do not inhibit the
cytochrome P450, seems to be equally useful in reducing
intraosseous hypertension.2,10
The syndrome is completely reversible over a period of a
few months, without sequelae of any kind.
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